Upgrade to SI Premium - Free Trial

Raymond James Reiterates Outperform Rating on Neurocrine Bio. (NBIX), Company is Well Positioned to Execute as COVID Dissipates

February 11, 2022 11:44 AM
Raymond James analyst Danielle Brill reiterated an Outperform rating and $125.00 price target on Neurocrine Bio. (NASDAQ: NBIX) following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles